Background {#Sec1}
==========

Both solid and hematologic malignancies are associated with an increased risk of thromboembolic events \[[@CR1]\]. One of the most commonly used risk-scoring systems for thrombosis, the Khorana Risk Score (KRS), was developed by studying patients with non-hematologic cancers receiving outpatient chemotherapy treatments. The KRS is based on body mass index (BMI) and white blood cell, hemoglobin, and platelet counts \[[@CR2]\]. The KRS has proven to be the best validated risk assessment model for predicting thrombotic events among patients with solid tumors, given the hypercoagulable state of solid tumor malignancies \[[@CR2], [@CR3]\]. Despite its initial application in the ambulatory setting, its utility in inpatient settings also became evident \[[@CR4]\].

However, the risk of developing thrombosis varies depending on the type of malignancy, and over the last decade, researchers have tried to identify the varying risks of thrombosis \[[@CR3]\]. Recent research has shown that the KRS cannot be used to predict thrombosis among patients with certain solid organ malignancies \[[@CR5], [@CR6]\]. Among patients with lymphoid malignancies, such as diffuse large B cell lymphoma, the KRS was found to be inadequate for stratifying thrombosis risk, and other factors were found to be more predictive of thrombosis \[[@CR7]\]. Therefore, a more specific prognostic scoring system was required to predict thrombosis in lymphomatous malignancies \[[@CR8], [@CR9]\].

Unlike patients with solid tumors, patients with acute leukemia commonly present with pancytopenia at the time of diagnosis \[[@CR10]\]. Paradoxically, there is a risk of thrombosis in thrombocytopenic patients with hematological malignancies, but management with anticoagulation is often curtailed \[[@CR11]\]. According to a 2017 meta-analysis, the incidence rate of thromboembolic events among patients with acute myeloid leukemia (AML) was approximately 6% \[[@CR1]\]. According to current literature, the KRS has not been validated among patients with AML \[[@CR12]\]. Furthermore, prophylactic and therapeutic management of thrombosis has not been standardized for patients with AML \[[@CR13]--[@CR15]\]. Thus, the goal of our current study was to validate the use of the KRS as a risk-scoring system for thrombosis among patients with AML.

Methods and materials {#Sec2}
=====================

Patients and sample acquisition {#Sec3}
-------------------------------

Using data from H. Lee Moffitt Cancer Center and Research Institution's Total Cancer Care Research Study, we retrospectively identified patients who were histologically confirmed with AML from 2000 to 2018. Patients with primary and secondary AML were included. Clinical and laboratory variables at the time of AML diagnosis (including age, sex, previous cancer history, use of growth factors, underlying coagulopathy, and white blood cell, hemoglobin, and platelet counts) were characterized and annotated using descriptive statistics. Information regarding venous thrombosis after AML diagnosis and prior thrombotic events before AML diagnosis were collected from individual patient chart reviews. Additional clinical information, including cytogenetics, AML risk stratification, treatment regimens, and Eastern Cooperative Oncology Group performance statuses, were also obtained. This study was approved by the H. Lee Moffitt Cancer Center and Research Institution Scientific Review Committee (MCC \#18648) and the University of South Florida Institutional Review Board (**Pro00025683)**. Study data were collected and managed by using REDCap electronic data capture tools hosted at the University of South Florida \[[@CR16]\].

Primary end point and outcome measure {#Sec4}
-------------------------------------

The primary end point of our study was the rate of venous thromboembolic event according to the KRS and arterial embolic events were excluded from our analysis. We included both superficial and deep vein thrombotic events as our end point. Thrombosis was counted as an event when VTE was confirmed by imaging modalities including venous duplex ultrasound and CT angiogram. Also, we counted VTE as an event when there is a clear documentation on the medical chart in patients who were transferred from another medical center.

KRS calculation and statistical analyses {#Sec5}
----------------------------------------

To calculate the KRS, we used complete blood count data from immediately before induction chemotherapy. Each of the following categories constituted a single point: pre-chemotherapy platelet count \> 350 × 10^9^/L, leukocyte count \> 11 × 10^9^/L, hemoglobin count \< 10 g/dL, the use of erythropoiesis-stimulating agents, and a BMI \> 35 kg/m^2^ \[[@CR2]\]. Intermediate-risk patients had 1 to 2 points, and high-risk patients had \> 3 points. A cancer type was designated as "other" with a score of zero indicating that it was not associated with thrombosis per KRS. The VTE rate was estimated with the Kaplan-Meier method, and univariate comparisons were completed using the log-rank test. A *P* value \< .05 was regarded as statistically significant. We performed additional multivariate analysis utilizing clinical and laboratory parameters such as age, gender, race, BMI, prior history of cancer, and albumin. All statistical analyses were performed using SPSS v24.0 (SAS Institute Inc., Cary, NC, USA) and GraphPad Prism 7.00 (GraphPad Software, La Jolla, California, USA).

Results {#Sec6}
=======

Patient characteristics {#Sec7}
-----------------------

A total of 867 AML patients were included in this study, of whom 44% (*n* = 383) and 56% (*n* = 483) had de novo and secondary AML, respectively. The median age at AML diagnosis was 75 years (range, 51--96), and the majority of patients were male (65%, *n* = 565). A total of 28% (*n* = 241) of patients had a prior history of cancer (hematologic malignancies, *n* = 34; solid tumors, *n* = 207). A total of 14% (*n* = 126), had a prior history of thrombosis, however information about whether it was venous or provoked was incomplete. A total of 12% (*n* = 101), 7% (*n* = 58), and 1% (*n* = 8) of patients were treated with erythropoietin-stimulating agents, granulocyte colony-stimulating factor, or granulocyte-macrophage colony-stimulating factor, respectively, before AML diagnosis. Eighty-four percent (*n* = 728) of patients were treated with growth factors of any type after AML diagnosis. The median BMI of patients was 27.1 (range, 14.8--103), and 5% (*n* = 47) of patients had a BMI \> 35. A total of 26% (*n* = 229) of patients had a white blood cell count ≥ 11 × 10^9^/L; 67% (*n* = 584) of patients had a hemoglobin count \< 10 g/L; and 1% (*n* = 10) of patients had a platelet count \> 350 × 109/L. Additional demographic profiles and clinical parameters are described in Table [1](#Tab1){ref-type="table"}.Table 1Additional clinical characteristics and demographic profiles of patientsPatient CharacteristicsValue (*N* = 867)Patient age median (range), y75 (51--96)Sex, No. (%) Male565 (65) Female302 (35)Race, No. (%) Caucasian801 (92) African American18 (2) Hispanic25 (3) Other19 (2)AML classification, No. (%) De novo AML383 (44) Secondary AML483 (56)AML risk stratification, No. (%) Favorable-risk group21 (2) Intermediate-risk group485 (56) Poor-risk group266 (31)History of prior or concurrent cancer, No. (%) Hematologic malignancies34 (4) Solid tumors207 (24)Prior thrombosis (arterial/venous)126 (14)Growth factors, No. (%) Before AML diagnosis167 (19) EPO101 (12) G-CSF58 (7) GM-CSF8 (1) Post AML diagnosis728 (84)Complete blood counts at diagnosis, No. (range) WBC (× 10^9^/L)3.165 (0.08--413.74) Hemoglobin (g/dL)9.3 (5.6--15.2) Platelet (× 10^9^/L)46 (1--800)Treatment regimen, No. (%) Chemotherapy250 (29) Hypomethylating agent240 (28) Best supportive care225 (26)BMI, No. (%)  ≤ 35 kg/m^2^820 (65)  \> 35 kg/m^2^47 (5)*Abbreviations*: *AML* acute myeloid leukemia, *BMI* body mass index, *EPO* erythropoietin, *G-CSF* granulocyte colony-stimulating factor, *GM-CSF* granulocyte-macrophage colony-stimulating factor, *WBC* white blood cells

KRS and thrombosis risk analyses {#Sec8}
--------------------------------

A total of 22% (*n* = 191), 51% (*n* = 445), 24% (*n* = 207), and 3% (*n* = 24) of patients had a KRS of 0, 1, 2, and 3, respectively **(**Table [2](#Tab2){ref-type="table"}**)**. A total of 42 thrombotic events were observed, with a median follow-up of 3 months (range, 0.1--307). A total of 3% (*n* = 6/191), 5% (*n* = 23/445), 6.3% (*n* = 13/207), and 0% (*n* = 0/24) of these thrombotic events occurred among patients with a KRS of 0, 1, 2, and 3, respectively **(**Fig. [1](#Fig1){ref-type="fig"}**)**. A log-rank (Mantel-Cox) test showed no statistical difference of thrombosis risk between individual subgroups (*P* = 0.1949). In the comparison between patients with KRS 0 vs. KRS 1--3, there was no statistical difference in the rates of VTE between these two groups (3% vs. 5%, *P* = 0.2555) **(**Table [2](#Tab2){ref-type="table"}**)**. In an additional multivariate analysis including age (HR 1.056, 95%CI 0.983--1.134, *P* = 0.135), gender (HR 1.118, 95%CI 0.466--2.678, *P* = 0.803), race (HR 0.998, 95%CI 0.977--1.021, *P* = 0.890), BMI (HR 1.030, 95%CI 0.984--1.079, *P* = 0.207), prior history of cancer (HR 0.422, 95%CI 0.129--1.387, *P* = 0.155), and albumin (HR 0.808, 95%CI 0.473--1.379, *P* = 0.434), there was no clinical or laboratory parameter that was significantly associated with increased risk of VTE.Table 2Khorana Risk Score and Thrombosis Event Correlation. Fisher's Exact test showed that there is no statistical VTE difference between AML patients with KRS 0 vs. KRS 1--3 (*P* = 0.2555). Also, a log-rank (Mantel-Cox) test showed no statistical difference of VTE risk between individual subgroups (*P* = 0.1949)Khorana ScoreNo. (%) of patients, *n* = 867No. (%) of thrombosis events0191 (22)6 (3)1445 (51)23 (5)2207 (24)13 (6.3)324 (3)0 (0)1, 2, 3, and 4 (all patients)867 (100)42 (5)Fig. 1Risk of Thrombosis. VTE rates are plotted based on Khorana Score over time. AML patients with KRS 3 and 4 are not included in the analysis since there was no observed VTE in these groups

Discussion {#Sec9}
==========

Patients with AML were shown to have an increased risk of thrombosis, and thrombotic episodes represent significant morbidity and mortality among AML patients \[[@CR17]--[@CR19]\]. Although the KRS is the most widely used validated risk assessment model for predicting thrombotic events, it was not developed specifically for AML patients. Current predictive and prognostic models that are widely used in clinical settings do not take into account several risk factors that are relevant to AML patients \[[@CR20], [@CR21]\]. Therefore, we performed a single-institution retrospective study to validate the use of KRS in assessing the risk of thrombosis among AML patients.

We observed an increased number of VTE among AML patients with a KRS of 1 to 3 compared to patients with KRS 0. However, there was no statistical difference of thrombosis risk between these groups. Furthermore, only a few patients had a KRS ≥ 3, indicating that the current KRS system is not optimal to categorize the thrombosis risk group. This limitation of the KRS for AML patients is largely due to unique clinical characteristics associated with this patient group (such as pancytopenia at the time of diagnosis). Moreover, the KRS system does not include other clinical parameters---such as female sex, older age, number of chronic comorbidities, and presence of a central venous catheter---that were previously shown to be associated with an increased risk of thrombosis among AML patients \[[@CR22]\]. Hematopoietic growth factors (erythropoietin, granulocyte colony-stimulating factor, and granulocyte-macrophage colony-stimulating factor) play a role in activating coagulation factors and cytokines that alter coagulation, modulate hemostasis, and cause platelet aggregation---all of which contribute to thrombotic events \[[@CR23]--[@CR27]\]. In addition, the KRS does not stratify by type of thrombosis, and arterial thromboembolism may be associated with greater morbidity and mortality than venous thromboembolism \[[@CR27], [@CR28]\].

The pathophysiology of arterial and venous thrombosis both follow the principles of Virchow's Triad: alterations in flow, abnormal cell and molecular properties, and altered blood vessel walls \[[@CR27]\]. The multifactorial pathogenesis of thrombosis in leukemia involves blast cells secreting prothrombotic tissue factor, cancer procoagulants, and cytokines. When combined with the release of growth factors, cytokines activate platelets \[[@CR11]\]. These interactions are multiplied when chemotherapy induces massive cell death, which may explain why thrombosis can occur while leukemic patients are thrombocytopenic \[[@CR22], [@CR29]\]. According to one study, the majority (75%) of thrombotic events consist of deep vein thrombosis/pulmonary embolism, cardiac events, and cerebrovascular accidents, \> 80% of which occur before or during induction chemotherapy \[[@CR30]\]. High-risk patients who are taking chemotherapy have been a highlighted sub-population in recent studies who may benefit from routine thromboprophylaxis (<https://www.nejm.org/doi/full/10.1056/NEJMoa1814630>, <https://www.nejm.org/doi/full/10.1056/NEJMoa1814468>).

In acute promyelocytic leukemia, several factors were related to a higher incidence of thrombosis: leukocytes \> 10 × 109/L (9% vs 4%, *P*  \< .01), M3-variant subtype (11% vs 4%, *P* = .02), fibrinogen \< 170 mg/dl (7% vs 3%, *P* = .02), and hemoglobin \> 10 g/dl (8% vs 4%, *P* = .03) \[[@CR31]\]. In addition to previously known prognostic factors, independent risk factors for thrombosis also include increasing age and cytogenetic risk \[[@CR32], [@CR33]\]. Recently, disseminated intravascular coagulation was found to be significantly predictive of venous and arterial thrombosis, with thrombosis incidence being approximately 10% among patients who were treated with multiple rounds of chemotherapy \[[@CR34]\]. Recent data suggest that malignant leukocytes mediate both disseminated intravascular coagulation and primary hyperfibrinolysis in acute promyelocytic leukemia \[[@CR35]\]. Additionally, both hyperleukocytosis and platelet aggregation seem to contribute to arterial thrombosis in acute leukemia \[[@CR36], [@CR37]\]. Collectively, these results suggest that further studies are warranted to develop an optimal thrombosis risk-scoring system that reflects the unique clinical and pathogenic features of AML patients.

Although limited by its retrospective nature, this study involved the experience of a single institution from 2000 to 2018, during which time the institution used the same diagnostic and treatment protocols and maintained follow-up data in a large comprehensive database. A large group of trained personnel conducted the extensive chart review but any threats to data quality was mitigated by using a centralized, organized extraction tool via REDCap. Another limitation of this study was the lack of routine screening for thrombotic events. Only symptomatic events were included, which may have falsely decreased observed frequency rates.

Conclusions {#Sec10}
===========

Among AML patients with a KRS of 1 to 3, we found a higher incidence of thrombotic events; however, the difference between these groups was not statistically significant. The proportion of patients with a KRS ≥ 3 was relatively low, which is largely due to pancytopenia, a common presentation among AML patients. These results suggest that the development of a better thrombotic risk-scoring system is warranted for AML patients.
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